Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (67)	12/2/2003 7:33:53 PM
From: mopgcw	Read Replies (1) \| Respond to of 276

Illumina Accelerates Genomic Research by Lowering Cost of 2003-12-02 06:03 (New York) Oligonucleotides to $0.11 Per Base Health/Medical Writers / Business Editors BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--Dec. 2, 2003 Illumina, Inc. (NASDAQ: ILMN) announced today that it has made significant enhancements to its Oligator(R) oligo synthesis technology, resulting in improved operational efficiency and capacity. As a result, the Company has introduced a new, volume-based pricing program that will again reduce the cost of oligonucleotide-based genetic analysis for the life science community. In 2002, Illumina began offering $0.16 per-base pricing which dramatically reduced researchers' costs. The new pricing schedule will allow researchers and institutions consuming large volumes of oligonucleotides to purchase oligos in plates for as low as $0.11 a base -- a significant reduction from current industry pricing. Illumina's proprietary Oligator synthesis technology is optimized for the production of plate-scale quantities of oligos for use in genotyping, sequencing, gene expression analysis, PCR, and other high-throughput research applications. Individual Oligator synthesizers are capable of producing greater than 3,000 oligos at a time in Illumina's highly integrated, automated, and LIMS-controlled manufacturing environment. In addition to serving the plate-based oligo market, Oligator oligo production supports the Company's SNP genotyping and gene expression offerings, both of which demand high-quality oligos. Tom Rosso, Product Line Manager, commented "Our Oligator DNA synthesis operation continues to deliver high quality and superior value to life scientists and organizations looking to lower the cost of large-scale genomics research. We're very pleased with the progress our manufacturing team has made in leveraging the Oligator platform and with the additional benefits we can now pass along to our growing, global customer base." Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine.